RetiVue DR, a point and shoot, non-mydriatic, widefield retinal camera for diabetic eye screening

Information

  • Research Project
  • 9409553
  • ApplicationId
    9409553
  • Core Project Number
    R44EY028484
  • Full Project Number
    1R44EY028484-01
  • Serial Number
    028484
  • FOA Number
    PAR-14-088
  • Sub Project Id
  • Project Start Date
    9/30/2017 - 7 years ago
  • Project End Date
    8/31/2019 - 5 years ago
  • Program Officer Name
    WUJEK, JEROME R
  • Budget Start Date
    9/30/2017 - 7 years ago
  • Budget End Date
    8/31/2018 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/12/2017 - 7 years ago
Organizations

RetiVue DR, a point and shoot, non-mydriatic, widefield retinal camera for diabetic eye screening

Project Summary Over the past two decades, diabetic retinopathy (DR) has become the leading cause of adult blindness in the US, affecting 40% of all diabetic patients and resulting in $500 million a year in direct medical costs. Vision loss due to DR is largely preventable and can be reduced by up to 90% with appropriate eye screening. However, in the US, less than 50% of diabetic patients receive a recommended yearly eye exam due to many factors that include lack of access to eye care professionals. Distributed tele-ophthalmic screening thru primary care clinics can potentially provide all diabetic patients cost- effective, yearly evaluations to detect DR and prevent vision loss. However, gold-standard sensitive detection of DR using standard retinal photography is complex and cumbersome process requiring up to 7 images per eye. This screening process cannot for all practical purposes be achieved without having highly trained ophthalmic photographers. RetiVue proposes to develop the RetiVue DR in collaboration with Olympus, to create the first handheld, non- mydriatic, 160 field of view, widefield DR screening camera. It will allow single photo capture of an area up to ten times greater than conventional fundus cameras, allowing sensitive detection of DR at its earliest time points. Full integration of RetiVue and Olympus hardware will enable the most advanced and highest image quality handheld retina camera on the market. Use of automated alignment, auto laser focus, and auto image capture will allow complex imaging of the retina to be performed simply by positioning the iris, requiring no user knowledge of retinal anatomy. We have established clinical proof of concept with our patented technology, but require several additional innovations in optical design, automated image recognition, and retinal image processing to enable a commercial device. We will for this proposal optimize our alignment system and laser based focusing system for widefield imaging, allowing automated alignment and focus to image the retina before eye movement occurs. We will develop a new method of widefield, non-mydriatic peripheral retinal imaging using multiple LED slit-beam projectors to allow rapid, segmental, sequential image capture of 90°, 120°, and 160° FOV on diabetic patients. Finally, we will create the most advanced retinal image processing algorithms to remove Purkinje haze which prevents conventional cameras from imaging beyond 45° FOV and enable seamless stitching of segmental peripheral retina images into a single widefield image.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R44
  • Administering IC
    EY
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    926693
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
    NEI:926693\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RETIVUE
  • Organization Department
  • Organization DUNS
    968571104
  • Organization City
    CHARLOTTESVILLE
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    229012922
  • Organization District
    UNITED STATES